Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Inclusion Criteria:

• Male or female, 18 to 70 years of age

• ≥6-month history of Hidradenitis suppurativa (HS)

• Total AN (abscess and inflammatory nodule) count ≥5

• HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage IIor III

Exclusion Criteria:

• Draining tunnel count >20

• Presence of another inflammatory condition or a skin condition that may interferewith study assessments

• Known to have immune deficiency or is immunocompromised

• Evidence or suspicion of active or latent tuberculosis

• History of opportunistic, chronic, or recurrent infection requiring chronicantibiotic use, serious or life-threatening infection within 2 months, or had aninfection requiring systemic antibiotics within 2 weeks

• Has active systemic candidiasis

• Unable to tolerate subcutaneous drug administration